Waltham, Mass. — August 14, 2025 — Leads & Copy — Xilio Therapeutics, Inc. (Nasdaq: XLO) reported pipeline progress, business updates, and financial results for the second quarter ended June 30, 2025. The company highlighted updated Phase 2 data at ASCO for vilastobart, demonstrating deep and durable responses and a differentiated safety profile. Xilio is on track to nominate first development candidates for wholly owned masked T cell engager programs in the second half of 2025 and reported $121.6 million in cash and cash equivalents as of June 30, 2025, with anticipated cash runway through the end of the third quarter of 2026.
René Russo, Pharm.D., president and chief executive officer of Xilio, said the company continued to make strong progress across its pipeline of novel tumor-activated immuno-oncology therapies during the second quarter. Russo added that with the company’s recent financing, they believe that they are well-positioned to execute on its strategic goals.
Pipeline Updates:
Vilastobart: Updated Phase 2 data presented at ASCO demonstrated a 26% objective response rate in heavily pre-treated metastatic MSS CRC patients without liver metastases. Xilio anticipates reporting additional data from the Phase 2 trial in the first half of 2026.
XTX301: Enrollment is complete in Phase 1A monotherapy dose escalation, and Phase 1B monotherapy dose expansion is ongoing.
XTX501: Advancing in IND-enabling studies with plans to submit an IND application in the middle of 2026.
Masked T Cell Engager Programs: Development candidate nominations are expected for PSMA, CLDN18.2, and STEAP1 programs in the third quarter of 2025, fourth quarter of 2025, and first half of 2026, respectively.
Corporate Updates:
In June 2025, Xilio closed a follow-on public offering, receiving initial gross proceeds of approximately $50.0 million. Akintunde (Tunde) Bello, Ph.D., was appointed to the company’s board of directors.
Second Quarter 2025 Financial Results:
Cash Position: Cash and cash equivalents were $121.6 million as of June 30, 2025, compared to $55.3 million as of December 31, 2024.
Collaboration and License Revenue: Collaboration and license revenue was $8.1 million for the quarter ended June 30, 2025, compared to $2.4 million for the quarter ended June 30, 2024.
R&D Expenses: R&D expenses were $15.3 million for the quarter ended June 30, 2025, compared to $11.2 million for the quarter ended June 30, 2024.
G&A Expenses: G&A expenses were $7.1 million for the quarter ended June 30, 2025, compared to $5.8 million for the quarter ended June 30, 2024.
Net Loss: Net loss was $15.8 million for the quarter ended June 30, 2025, compared to $13.9 million for the quarter ended June 30, 2024.
Xilio anticipates that its cash and cash equivalents as of June 30, 2025 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements through the end of the third quarter of 2026.
Investor Contact:
investors@xiliotx.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
Source: Xilio Therapeutics
